全球移植物抗宿主病 (GvHD) 治疗市场：流行病学、管道分析、市场预测（2022-2027 年）

移植物抗宿主病 (GvHD) 治疗的市场规模预计在预计期间以 7.44% 的复合年增长率增长。

皮质类固醇具有超过 28.97% 的巨大市场份额，因为它们被广泛推荐用于一线。急性 GvHD (aGvHD) 也显示出 34.73% 的重要份额，因为 30-50% 的造血干细胞移植患者发展为急性 GvHD。

本报告调查了全球移植物抗宿主病 (GvHD) 治疗市场，概述了 GvHD、8 个主要国家的 HSCT 和异基因 HSCT 以及 8 个主要国家的 aGvHD 和异基因 HSCT 的变化和预测。总结了cGvHD病例数的变化和预测、8个主要国家市场GvHD收入的变化和预测、上市药物和在研药物分析、临床试验趋势、竞争环境、主要公司概况等。

目录

第 1 章 GvHD 概述

第 2 章流行病学/GvHD 概述

• HSCT及类似HSCT在8个主要国家市场的趋势和预测
• 8个主要市场的 HSCT 与异基因 HSCT 对比分析
• 8个主要国家市场中aGvHD和cGvHD病例数量的变化和预测
• 8个主要国家市场aGvHD和cGvHD发病率对比分析
• 美国：HSCT 和类似 HSCT 的过渡/预测
• 美国：HSCT与异基因HSCT的比较分析
• 美国：aGvHD 和 cGvHD 病例数量的变化和预测
• 美国：aGvHD 和 cGvHD 发病率的比较分析
• 中国：HSCT 和类似 HSCT 的转变/预测
• 中国：HSCT与异基因HSCT的比较分析
• 中国：aGvHD 和 cGvHD 病例数的变化和预测
• 中国：aGvHD 和 cGvHD 发病率的比较分析
• 德国：HSCT 和类似 HSCT 的过渡/预测
• 德国：HSCT与异基因HSCT的比较分析
• 德国：aGvHD 和 cGvHD 病例数量的变化和预测
• 德国：aGvHD 和 cGvHD 发病率的比较分析
• 日本：HSCT 和类似 HSCT 的过渡/预测
• 日本：HSCT与异基因HSCT的比较分析
• 日本：aGvHD 和 cGvHD 病例数量的变化和预测
• 日本：aGvHD 和 cGvHD 发病率的比较分析
• 法国：HSCT 和类似 HSCT 的过渡/预测
• 法国：HSCT与异基因HSCT的比较分析
• 法国：aGvHD 和 cGvHD 病例数量的变化和预测
• 法国：aGvHD 和 cGvHD 发病率的比较分析
• 义大利：HSCT 和类似 HSCT 的过渡/预测
• 义大利：HSCT与异基因HSCT的比较分析
• 义大利：aGvHD 和 cGvHD 病例数量的变化和预测
• 义大利：aGvHD 和 cGvHD 发病率的比较分析
• 英国：HSCT 和类似 HSCT 的过渡/预测
• 英国：HSCT 与异基因 HSCT 的比较分析
• 英国：aGvHD 和 cGvHD 病例数量的变化和预测
• 英国：aGvHD 和 cGvHD 发生率的比较分析
• 西班牙：HSCT 和类似 HSCT 的过渡/预测
• 西班牙：HSCT与异基因HSCT的比较分析
• 西班牙：aGvHD 和 cGvHD 病例数量的变化和预测
• 西班牙：aGvHD 和 cGvHD 发病率的比较分析

第 3 章 GvHD 市场规模/概述

• 8个主要市场的 GvHD 收入趋势和预测
• 8个主要市场的 GvHD 收入趋势和预测：快照
• 8个主要国家市场上主要批准和非适应症的 GvHD 药物
• 8个主要市场的收入趋势/预测：按治疗类型/性别/药物类别
• 美国：GvHD 收入的趋势和预测
• 美国：GvHD 收入趋势/预测：快照
• 美国：收入趋势/预测：按治疗类型/性别/药物类别
• 中国：GvHD 收入的趋势和预测
• 中国：GvHD 收入趋势/预测：快照
• 中国：收入趋势/预测：按治疗类型/性别/药物类别
• 德国：GvHD 收入的趋势和预测
• 德国：GvHD 收入趋势/预测：快照
• 德国：收入趋势/预测：治疗类型/性别/药物类别
• 日本：GvHD 收入的趋势和预测
• 日本：GvHD 收入趋势/预测：快照
• 日本：收入趋势/预测：治疗类型/性别/药物类别
• 法国：GvHD 收入的趋势和预测
• 法国：GvHD 收益趋势/预测：快照
• 法国：收入趋势/预测：治疗类型/性别/药物类别
• 义大利：GvHD 收入的趋势和预测
• 义大利：GvHD 收益趋势/预测：快照
• 义大利：收入趋势/预测：治疗类型/性别/药物类别
• 英国：GvHD 收入的趋势和预测
• 英国：GvHD 收入趋势/预测：快照
• 英国：收入趋势/预测：按治疗类型/性别/药物类别
• 西班牙：GvHD 收入的趋势和预测
• 西班牙：GvHD 收入趋势/预测：快照
• 西班牙：收入趋势/预测：按治疗类型/性别/药物类别

第 4 章 GvHD 上市药物概述

• GvHD 非处方药：概述
• GvHD 非处方药：总结

第 5 章 GvHD 管线药物概述

• GvHD 管线药物：概述
• GvHD 管道药物：快照
• GvHD 管道药物概述/快照：按疾病类型
• GvHD 管道药物概述/快照：按开发阶段
• GvHD 管道药物概述 □ 快照：按给药途径
• GvHD 管道药物概述/快照：按作用机制
• GvHD 管道药物概述/快照：按分子类型
• GvHD 管道药物概述/快照：按地区

第 6 章 GvHD：临床试验概述

• GvHD 临床试验总结：快照
• GvHD 临床试验概述：按招募状态
• GvHD 临床试验概述：按产品类型
• GvHD 临床试验概述：按给药途径
• GvHD 临床试验概述：按分子类型
• GvHD 临床试验概述：按地区划分

第 7 章 GvHD：市场动态

• 市场促进因素
• 市场抑制因素
• 市场趋势

第 8 章 GvHD：竞争态势

• GvHD 竞赛：上市药物
• 未满足的需求/战略建议
• 非适应症和晚期药物的竞争性评估
• 主要公司简介
• GvHD 药物市场的竞争情景
• 其他领先的公司简介
• 主要公司概览
• GvHD 竞争：管道药物
• 主要初创企业简介
• 主要初创公司概览
• 其他领先公司的简介

第 9 章 GvHD：其他

• 临时药品审批时间表
• 主要监管名称
• 主要里程碑
• 合同/协作
• 暂停/停产产品

第 10 章附录

The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022-2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.

The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.

SEGMENT ANALYSIS

• Corticosteroids accounted for the significant share of more than 28.97% in the global GvHD treatment market due to its wide recommendation in front line setting.
• The acute GVHD (aGVHD) accounted for a significant share of 34.73% in the global graft versus host disease (GVHD) treatment market due to 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
• Males are accounted for the significant share of 59.64% in the global GvHD treatment market due to rise in number of hematopoietic stem cell transplantations.

Market Segmentation by Drug Class

• Corticosteroids
• Kinase Inhibitors
• Calcineurin Inhibitors
• TNF-Alpha Inhibitors
• Other Class of Drugs

Market Segmentation by Treatment Type

• GVHD Prophylaxis
• Chronic GVHD
• Acute GVHD

Market Segmentation by Gender Type

• Males
• Females

GEOGRAPHIC ANALYSIS

• The United States dominated the graft versus host disease (GVHD) treatment market by geography. However, China is expected to grow faster with a high CAGR in the market. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.

Market Segmentation by Geography

• North America
  • US
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
• APAC
  • China
  • Japan

VENDOR ANALYSIS

• With more than 134+ molecules in various stages of development, it is expected that new vendors are likely to enter into the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.

Key Players

• Incyte
• Pharmacyclics
• Bristol-Myers Squibb
• JCR Pharmaceuticals Co., Ltd.
• Takeda Pharmaceutical Co Ltd (Takeda)
• MaaT Pharma
• XeniKos
• Medac GmbH
• Mesoblast
• Kadmon
• Jazz Pharmaceuticals
• Gsk
• Novartis
• Syndax Pharmaceuticals Inc

Other Prominent Vendors

• Neovii
• ElsaLys Biotech
• Mallinckrodt
• Regimmune
• Roche
• Altrubio
• CTTQ
• Equillium
• Janssen (johnson & johnson)
• ASC Therapeutics
• MSD
• Genentech
• Sun Pharma
• Mink Therapeutics
• Pluristem

The Report Covers The following details:

• Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
• Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
• Historical, current, and projected patient pool of GVHD in the eight major markets (8MM) for the 2018 - 2027 period
• Disease, Gender, and Drug Class segmentations of the GVHD in the eight major markets (8MM)
• Historical, current, and projected market size & forecast of GVHD in eight major markets (8MM) for the 2018 - 2027 period
• In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
• Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape
• Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
• Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
• Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GVHD across the complete product development cycle, including all clinical and non-clinical stages
• Detailed overview of clinical trial activities and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for GVHD across all clinical stages
• Coverage of dormant and discontinued pipeline projects along with the reasons across GVHD
• Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the GVHD space

TABLE OF CONTENTS

CHAPTER - 1 GVHD OVERVIEW

• Graft Versus Host Disease - An Overview

CHAPTER - 2 GVHD EPIDEMIOLOGY & OVERVIEW

• 8MM Historic & Projected Volume of HSCT & Allogeneic - HSCT
• 8MM Comparative Analysis of HSCT & Allogeneic - HSCT
• 8MM Historic & Projected Volume of incidence of aGVHD & cGVHD
• 8MM Comparative Analysis of incidence of aGVHD & cGVHD
• US Historic & Projected Volume of HSCT & Allogeneic - HSCT
• US Comparative Analysis of HSCT & Allogeneic - HSCT
• US Historic & Projected Volume of incidence of aGVHD & cGVHD
• US Comparative Analysis of incidence of aGVHD & cGVHD
• China Historic & Projected Volume of HSCT & Allogeneic - HSCT
• China Comparative Analysis of HSCT & Allogeneic - HSCT
• China Historic & Projected Volume of incidence of aGVHD & cGVHD
• China Comparative Analysis of incidence of aGVHD & cGVHD
• Germany Historic & Projected Volume of HSCT & Allogeneic - HSCT
• Germany Comparative Analysis of HSCT & Allogeneic - HSCT
• Germany Historic & Projected Volume of incidence of aGVHD & cGVHD
• Germany Comparative Analysis of incidence of aGVHD & cGVHD
• Japan Historic & Projected Volume of HSCT & Allogeneic - HSCT
• Japan Comparative Analysis of HSCT & Allogeneic - HSCT
• Japan Historic & Projected Volume of incidence of aGVHD & cGVHD
• Japan Comparative Analysis of incidence of aGVHD & cGVHD
• France Historic & Projected Volume of HSCT & Allogeneic - HSCT
• France Comparative Analysis of HSCT & Allogeneic - HSCT
• France Historic & Projected Volume of incidence of aGVHD & cGVHD
• France Comparative Analysis of incidence of aGVHD & cGVHD
• Italy Historic & Projected Volume of HSCT & Allogeneic - HSCT
• Italy Comparative Analysis of HSCT & Allogeneic - HSCT
• Italy Historic & Projected Volume of incidence of aGVHD & cGVHD
• Italy Comparative Analysis of incidence of aGVHD & cGVHD
• UK Historic & Projected Volume of HSCT & Allogeneic - HSCT
• UK Comparative Analysis of HSCT & Allogeneic - HSCT
• UK Historic & Projected Volume of incidence of aGVHD & cGVHD
• UK Comparative Analysis of incidence of aGVHD & cGVHD
• Spain Historic & Projected Volume of HSCT & Allogeneic - HSCT
• Spain Comparative Analysis of HSCT & Allogeneic - HSCT
• Spain Historic & Projected Volume of incidence of aGVHD & cGVHD
• Spain Comparative Analysis of incidence of aGVHD & cGVHD

CHAPTER - 3 GVHD MARKET SIZE & OVERVIEW

• 8MM Historic & Projected Revenue of GVHD
• 8MM Historic & Projected Revenue of GVHD Snapshot
• 8MM Major Approved & Off-label Drugs in GVHD
• 8MM Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
• US Historic & Projected Revenue of GVHD
• US Historic & Projected Revenue of GVHD Snapshot
• US Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
• China Historic & Projected Revenue of GVHD
• China Historic & Projected Revenue of GVHD Snapshot
• China Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
• Germany Historic & Projected Revenue of GVHD
• Germany Historic & Projected Revenue of GVHD Snapshot
• Germany Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
• Japan Historic & Projected Revenue of GVHD
• Japan Historic & Projected Revenue of GVHD Snapshot
• Japan Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
• France Historic & Projected Revenue of GVHD
• France Historic & Projected Revenue of GVHD Snapshot
• France Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
• Italy Historic & Projected Revenue of GVHD
• Italy Historic & Projected Revenue of GVHD Snapshot
• Italy Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
• UK Historic & Projected Revenue of GVHD
• UK Historic & Projected Revenue of GVHD Snapshot
• UK Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
• Spain Historic & Projected Revenue of GVHD
• Spain Historic & Projected Revenue of GVHD Snapshot
• Spain Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class

CHAPTER - 4 GVHD MARKETED DRUGS OVERVIEW

• GVHD Marketed Drugs - An Overview
• GVHD Marketed Drugs - Summary

CHAPTER - 5 GVHD PIPELINE DRUGS OVERVIEW

• GVHD Pipeline Drugs - An Overview
• GVHD Pipeline Drugs - Snapshot
• GVHD Pipeline Drugs Overview & Snapshot - By Disease type
• GVHD Pipeline Drugs Overview & Snapshot - By Development Phase
• GVHD Pipeline Drugs Overview & Snapshot - By Route of Administration
• GVHD Pipeline Drugs Overview & Snapshot - By Mechanism of Action
• GVHD Pipeline Drugs Overview & Snapshot - By Molecule type
• GVHD Pipeline Drugs Overview & Snapshot - By Geography type

CHAPTER - 6 GVHD CLINICAL TRIALS OVERVIEW

• GVHD Clinical Trials Overview Snapshot
• GVHD Clinical Trials Overview - By Recruitment Status
• GVHD Clinical Trials Overview - By Product type
• GVHD Clinical Trials Overview - By Route of Administration
• GVHD Clinical Trials Overview - By Molecule type
• GVHD Clinical Trials Overview - By Geography type

CHAPTER - 7 GVHD MARKET DYNAMICS

• GVHD Treatment Market Drivers
• GVHD Treatment Market Constraints
• GVHD Treatment Market Trends

CHAPTER - 8 GVHD COMPETITIVE LANDSCAPE

• GVHD Competitive Landscape - Marketed Drugs
• Unmet Needs & Strategic Recommendations
• Competitive Assessment of Off-label & Late-stage Drugs
• Key Company Profiles
• Competitive Scenario of GVHD Treatment Market
• Other Prominent Company Profiles
• Key Company Overviews
• GVHD Competitive Landscape - Pipeline Drugs
• Key Emerging Company Profiles
• Key Emerging Company Overviews
• Other Prominent Company Profiles

CHAPTER - 9 GVHD MISCELLANEOUS

• Key Tentative Drug Approvals Timeline
• Key Regulatory Designations
• Key Milestones
• Deals & Collaborations
• Inactive/Discontinued/Dormant Products

CHAPTER - 10 APPENDIX

• About Arizton
• Research Methodology
• List of Abbreviations

LIST OF EXHIBITS

• Exhibit 1 HISTORIC & PROJECTED VOLUME OF HSCT IN 8 MAJOR MARKETS
• Exhibit 2 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN 8 MAJOR MARKETS
• Exhibit 3 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2018-2020)
• Exhibit 4 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2021 - 2027)
• Exhibit 5 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN 8 MAJOR MARKETS

Exhibit 6 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN 8 MAJOR MARKETS

• Exhibit 7 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2018-2020)
• Exhibit 8 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2021-2027)
• Exhibit 9 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED STATES
• Exhibit 10 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED STATES
• Exhibit 11 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2018-2020)

Exhibit 12 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2021-2027)

• Exhibit 13 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED STATES
• Exhibit 14 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED STATES
• Exhibit 15 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2018-2020)
• Exhibit 16 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2021-2027)
• Exhibit 17 HISTORIC & PROJECTED VOLUME OF HSCT IN CHINA

Exhibit 18 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN CHINA

• Exhibit 19 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2018-2020)
• Exhibit 20 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2021-2027)
• Exhibit 21 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN CHINA

Exhibit 22 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN CHINA

• Exhibit 23 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2018-2020)
• Exhibit 24 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2021-2027)
• Exhibit 25 HISTORIC & PROJECTED VOLUME OF HSCT IN GERMANY

Exhibit 26 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN GERMANY

• Exhibit 27 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2018-2020)
• Exhibit 28 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2021-2027)
• Exhibit 29 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN GERMANY

Exhibit 30 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN GERMANY

• Exhibit 31 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2018-2020)
• Exhibit 32 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2021-2027)
• Exhibit 33 HISTORIC & PROJECTED VOLUME OF HSCT IN JAPAN
• Exhibit 34 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN JAPAN
• Exhibit 35 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2018-2020)
• Exhibit 36 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2021-2027)
• Exhibit 37 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN JAPAN

Exhibit 38 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN JAPAN

• Exhibit 39 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2018-2020)
• Exhibit 40 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2021-2027)
• Exhibit 41 HISTORIC & PROJECTED VOLUME OF HSCT IN FRANCE
• Exhibit 42 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN FRANCE
• Exhibit 43 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2018-2020)

Exhibit 44 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2021-2027)

• Exhibit 45 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN FRANCE

Exhibit 46 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN FRANCE

• Exhibit 47 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2018-2020)
• Exhibit 48 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2021-2027)
• Exhibit 49 HISTORIC & PROJECTED VOLUME OF HSCT IN ITALY

Exhibit 50 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN ITALY

• Exhibit 51 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2018-2020)
• Exhibit 52 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2021-2027)
• Exhibit 53 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN ITALY

Exhibit 54 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN ITALY

• Exhibit 55 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2018-2020)
• Exhibit 56 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2021-2027)
• Exhibit 57 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED KINGDOM

Exhibit 58 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED KINGDOM

• Exhibit 59 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2018-2020)
• Exhibit 60 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2021-2027)
• Exhibit 61 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED KINGDOM

Exhibit 62 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED KINGDOM

• Exhibit 63 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2018-2020)
• Exhibit 64 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2021-2027)
• Exhibit 65 HISTORIC & PROJECTED VOLUME OF HSCT IN SPAIN

Exhibit 66 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN SPAIN

• Exhibit 67 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2018-2020)
• Exhibit 68 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2021-2027)
• Exhibit 69 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN SPAIN

Exhibit 70 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN SPAIN

• Exhibit 71 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2018-2020)
• Exhibit 72 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2021-2027)
• Exhibit 73 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN 8 MAJOR MARKETS
• Exhibit 74 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN 8 MAJOR MARKETS
• Exhibit 75 MAJOR APPROVED & OFF-LABEL DRUGS IN GVHD TREATMENT MARKET
• Exhibit 76 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN 8 MAJOR MARKETS
• Exhibit 77 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN 8 MAJOR MARKETS
• Exhibit 78 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN 8 MAJOR MARKETS
• Exhibit 79 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED STATES
• Exhibit 80 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED STATES
• Exhibit 81 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED STATES
• Exhibit 82 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED STATES
• Exhibit 83 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED STATES
• Exhibit 84 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN CHINA
• Exhibit 85 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN CHINA
• Exhibit 86 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN CHINA
• Exhibit 87 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN CHINA
• Exhibit 88 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN CHINA
• Exhibit 89 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN GERMANY
• Exhibit 90 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN GERMANY
• Exhibit 91 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN GERMANY
• Exhibit 92 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN GERMANY
• Exhibit 93 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN GERMANY
• Exhibit 94 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN JAPAN
• Exhibit 95 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN JAPAN
• Exhibit 96 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN JAPAN
• Exhibit 97 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN JAPAN
• Exhibit 98 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN JAPAN
• Exhibit 99 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN FRANCE
• Exhibit 100 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN FRANCE
• Exhibit 101 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN FRANCE
• Exhibit 102 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN FRANCE
• Exhibit 103 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN FRANCE
• Exhibit 104 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN ITALY
• Exhibit 105 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN ITALY
• Exhibit 106 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN ITALY
• Exhibit 107 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN ITALY
• Exhibit 108 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN ITALY
• Exhibit 109 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED KINGDOM
• Exhibit 110 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED KINGDOM
• Exhibit 111 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED KINGDOM
• Exhibit 112 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED KINGDOM
• Exhibit 113 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED KINGDOM
• Exhibit 114 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN SPAIN
• Exhibit 115 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN SPAIN
• Exhibit 116 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN SPAIN
• Exhibit 117 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN SPAIN
• Exhibit 118 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN SPAIN
• Exhibit 119 MARKETED DRUGS OVERVIEW IN GVHD TREATMENT MARKET
• Exhibit 120 GVHD PIPELINE DRUGS OVERVIEW SNAPSHOT
• Exhibit 121 GVHD PIPELINE DRUGS LANDSCAPE SNAPSHOT
• Exhibit 122 GVHD PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
• Exhibit 123 GVHD PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
• Exhibit 124 GVHD PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
• Exhibit 125 GVHD PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
• Exhibit 126 GVHD PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
• Exhibit 127 GVHD PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
• Exhibit 128 KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN GVHD
• Exhibit 129 KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN GVHD
• Exhibit 130 INACTIVE/DISCONTINUED PIPELINE DRUGS IN GVHD
• Exhibit 131 COMPETITIVE ASSESSMENT OF GVHD PROPHYLAXIS OFF-LABEL & LATE-STAGE PIPELINE DRUGS
• Exhibit 132 COMPETITIVE ASSESSMENT OF ACUTE GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
• Exhibit 133 COMPETITIVE ASSESSMENT OF CHRONIC GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
• Exhibit 134 GVHD CLINICAL TRIALS OVERVIEW SNAPSHOT

LIST OF TABLES

Table 1 KEY MARKET DRIVERS IN GVHD TREATMENT MARKET

Table 2 KEY MARKET CONSTRAINTS IN GVHD TREATMENT MARKET

Table 3 KEY MARKET TRENDS IN GVHD TREATMENT MARKET

Table 4 COMPETITIVE LANDSCAPE OF MARKETED DRUGS IN GVHD TREATMENT MARKET

Table 5 COMPETITIVE SCENARIO OF GVHD TREATMENT MARKET

Table 6 COMPETITIVE LANDSCAPE OF PIPELINE DRUGS IN GVHD TREATMENT MARKET